Morgan Stanley Maintains Overweight on Immix Biopharma, Lowers Price Target to $19
Morgan Stanley analyst Judah Frommer maintains Immix Biopharma (NASDAQ:IMMX) with a Overweight and lowers the price target from $20 to $19.
Read original at benzingaStocks · News reference
Immix Biopharma shares are trading lower. A report suggested that a fugitive worked as an executive for the company.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 20, 2026, 7:43 PM
- Checked
- Jul 20, 2026, 7:43 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $25
HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $20 to $25.
Read original at benzingaNeedham Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $21
Needham analyst Gil Blum initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Buy rating and announces Price Target of $21.
Read original at benzinga